Naber SK, Knudsen AB, Zauber AG, et al. - Researchers sought to determine if multitarget stool DNA (mtSDNA) testing vs other colorectal cancer (CRC) screening strategies reimbursed by the Centers for Medicare and Medicaid Services (CMS) is a cost-effective alternative. Using three independently-developed microsimulation models, they simulated a cohort of previously unscreened US 65-year-olds who were screened with triennial mtSDNA testing or one of six other reimbursed screening strategies. Outcomes revealed that triennial mtSDNA screening vs no screening leads to a reduction in CRC incidence and mortality at acceptable costs. However, triennial mtSDNA screening vs nearly all other CRC screening strategies reimbursed by CMS appeared less effective and considerably more costly, making it an inefficient screening option.